{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:06:06Z","timestamp":1793502366620,"version":"4.5.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background &amp; Aims<\/jats:title>\n                    <jats:p>Mirikizumab, an IL-23 p19\u2013targeting monoclonal antibody, is approved for moderate-to-severe ulcerative colitis (UC). Real-world evidence on its effectiveness and safety remains limited. We evaluated its effectiveness and safety in a real-world setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective multicenter study included adult UC patients treated with mirikizumab at 5 Italian centers (June 2024-October 2025), with\u2009\u226524\u2009weeks of follow-up. The primary outcome was clinical remission (CR, pMS\u2009\u2264\u20092 with rectal bleeding 0) at week(w)12. Secondary outcomes included intestinal ultrasound (IUS) remission, endoscopic remission, bowel urgency (BU) remission, fecal calprotectin (FC) normalization, and safety profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 236 patients (60.2% male; median age 47) were included. 77.5% had prior exposure to advanced therapy. Mirikizumab significantly reduced pMS at w12 and w24 (both P\u2009&amp;lt;\u2009.001), with clinical remission in 46.6% and 55.5%, respectively. Mayo endoscopic score improved at both timepoints (P\u2009&amp;lt;\u2009.01 and P\u2009&amp;lt;\u2009.001) with 38% achieving endoscopic remission at w24. IUS remission was nonsignificant at w12 but significant at w24 (P\u2009&amp;lt;\u2009.0001). BU and FC improved at both timepoints (P\u2009&amp;lt;\u2009.001). Remission rates were similar in biologic-naive and biologic-exposed patients. Discontinuations were uncommon, adverse events were infrequent and non-serious, and liver tests showed no clinically relevant changes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this real-world multicenter cohort, mirikizumab was associated with meaningful improvements across clinical, endoscopic, biochemical, and ultrasound outcomes, with low discontinuation rates and a favorable safety profile through 24\u2009weeks. These findings support the effectiveness of selective IL-23 inhibition in routine care, including in patients with prior exposure to advanced therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjag062","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T11:40:44Z","timestamp":1776253244000},"source":"Crossref","is-referenced-by-count":2,"title":["Effectiveness and safety of mirikizumab in patients with moderate-to-severe ulcerative colitis: the miri real multicenter study"],"prefix":"10.1093","volume":"20","author":[{"given":"Ferdinando","family":"D\u2019Amico","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Fanizzi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele , Milan,","place":["Italy"]},{"name":"Faculty of Medicine and Surgery, Vita e Salute San Raffaele University , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8543-4355","authenticated-orcid":false,"given":"Arianna","family":"Dal Buono","sequence":"additional","affiliation":[{"name":"IBD Center, Department of Gastroenterology, IRCCS Humanitas Research Hospital , Milan,","place":["Italy"]},{"name":"Department of Biomedical Sciences, Humanitas University , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7277-1053","authenticated-orcid":false,"given":"Roberto","family":"Gabbiadini","sequence":"additional","affiliation":[{"name":"IBD Center, Department of Gastroenterology, IRCCS Humanitas Research Hospital , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9554-4785","authenticated-orcid":false,"given":"Olga M","family":"Nardone","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Department of Public Health, University of Naples Federico II , Naples,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Zilli","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Allocca","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia M","family":"Lauriola","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Surgery, Vita e Salute San Raffaele University , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1092-0033","authenticated-orcid":false,"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Western University , London, ON,","place":["Canada"]},{"name":"Division of Gastroenterology, Department of Medicine, Western University , London, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2536-6618","authenticated-orcid":false,"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[{"name":"Northwestern Medicine Digestive Health Institute Chicago, IL,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5623-2968","authenticated-orcid":false,"given":"Gionata","family":"Fiorino","sequence":"additional","affiliation":[{"name":"IBD Unit, San Camillo-Forlanini Hospital , Rome,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Castiglione","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II , Naples,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Massimino","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Surgery, Vita e Salute San Raffaele University , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Mastronardi","sequence":"additional","affiliation":[{"name":"UOC - Gastroenterologia IBD, National Institute of Gastroenterology De Bellis , Castellana Grotte,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Armuzzi","sequence":"additional","affiliation":[{"name":"IBD Center, Department of Gastroenterology, IRCCS Humanitas Research Hospital , Milan,","place":["Italy"]},{"name":"Department of Biomedical Sciences, Humanitas University , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele , Milan,","place":["Italy"]},{"name":"Faculty of Medicine and Surgery, Vita e Salute San Raffaele University , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,7]]},"reference":[{"key":"2026060719282409500_jjag062-B1","first-page":"1606","volume-title":"The Lancet","author":"Orda\u00ccs","year":"2012"},{"key":"2026060719282409500_jjag062-B2","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2026060719282409500_jjag062-B3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1053\/j.gastro.2024.05.036","article-title":"Targeting the interleukin 23 pathway in inflammatory bowel disease","volume":"168","author":"Bourgonje","year":"2025","journal-title":"Gastroenterology"},{"key":"2026060719282409500_jjag062-B4","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1124\/jpet.122.001512","article-title":"Generation and characterization of mirikizumab, a humanized monoclonal antibody targeting the p19 subunit of IL-23","volume":"387","author":"Steere","year":"2023","journal-title":"J Pharmacol Exp Ther."},{"key":"2026060719282409500_jjag062-B5","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1056\/nejmoa2207940","article-title":"Mirikizumab as induction and maintenance therapy for ulcerative colitis","volume":"388","author":"D\u2019Haens","year":"2023","journal-title":"Engl J Med."},{"key":"2026060719282409500_jjag062-B6","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1093\/ibd\/izae253","article-title":"Three-year efficacy and safety of mirikizumab following 152 weeks of continuous treatment for ulcerative colitis: results from the LUCENT-3 open-label extension study","volume":"31","author":"Sands","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"2026060719282409500_jjag062-B7","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.cgh.2012.02.004","article-title":"Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population","volume":"10","author":"Ha","year":"2012","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2026060719282409500_jjag062-B8","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1177\/2050640620980203","article-title":"Milan ultrasound criteria are accurate in assessing disease activity in ulcerative colitis: external validation","volume":"9","author":"Allocca","year":"2021","journal-title":"United European Gastroenterol J"},{"key":"2026060719282409500_jjag062-B9","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1111\/apt.70140","article-title":"Real-world effectiveness and safety of mirikizumab induction therapy in patients with ulcerative colitis: a multicentre retrospective observational study","volume":"61","author":"Takagi","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"2026060719282409500_jjag062-B10","doi-asserted-by":"publisher","first-page":"e0334897","DOI":"10.1371\/journal.pone.0334897","article-title":"Sequencing Therapy for Optimal Response in Mirikizumab (STORM)-study: a tertiary referral center study on patients with therapy-refractory ulcerative colitis","volume":"20","author":"Kubesch","year":"2025","journal-title":"PLoS One"},{"key":"2026060719282409500_jjag062-B11","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1007\/s10620-025-08950-y","article-title":"Mirikizumab in the treatment of ulcerative colitis: initial real-world data in a population from a large tertiary center","volume":"70","author":"St-Pierre","year":"2025","journal-title":"Dig Dis Sci"},{"key":"2026060719282409500_jjag062-B12","doi-asserted-by":"publisher","first-page":"4510","DOI":"10.1007\/s12325-025-03296-3","article-title":"Broad impact of bowel urgency in ulcerative colitis and Crohn\u2019s disease: US, European, and Japanese Patient and Healthcare Professional Perspectives from the Communicating Needs and Features of IBD Experiences (CONFIDE) Survey","volume":"42","author":"Rubin","year":"2025","journal-title":"Adv Ther"},{"key":"2026060719282409500_jjag062-B13","doi-asserted-by":"publisher","DOI":"10.1002\/ueg2.70129","article-title":"Bowel urgency improvement correlates with clinical, biochemical, and intestinal ultrasound improvements in inflammatory bowel disease: a cross sectional multicenter study","volume":"14","author":"D\u2019Amico","year":"2026","journal-title":"United European Gastroenterol J."},{"key":"2026060719282409500_jjag062-B14","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1093\/ecco-jcc\/jjad071","article-title":"Early intestinal ultrasound predicts long-term endoscopic response to biologics in ulcerative colitis","volume":"17","author":"Allocca","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2026060719282409500_jjag062-B15","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf124","article-title":"Mirikizumab impact on disease clearance in patients with moderately to severely active ulcerative colitis: analysis of a pre-specified LUCENT trial endpoint","author":"Colombel","year":"2025","journal-title":"J Crohns Colitis"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/20\/6\/jjag062\/68485505\/jjag062.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/20\/6\/jjag062\/68485505\/jjag062.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T23:28:29Z","timestamp":1780874909000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjag062\/8703529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,7]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjag062","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,6]]},"article-number":"jjag062"}}